EGFR and neoplasm: The recent biomarker analysis from PARADIGM suggests that tumor-sidedness may be a surrogate marker for tumor biology; however, patients may be negatively hyperselected for anti-EGFR therapy with ctDNA analysis.29 This hypothesis warrants further study.